India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma. More
-
-
Sponsored By:
-
Sponsored By:
RHHBY
Recent Articles
AstraZeneca Plans 2,300 More Job Cuts
AstraZeneca will trim its payroll by another 2,300 jobs, just days after cutting 1,600 other workers, as part of its latest restructuring. More
FDA Warns Docs as More Fake Cancer Drugs Hit U.S.
The FDA is warning doctors that it has found another counterfeit batch of the cancer-fighting drug Avastin that contains no active ingredients. More
Biotech Movers: Keryx Jumps, Sarepta Slips
Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More
FDA Approves Avastin for Continued Cancer Treatment
The FDA on Wednesday approved the use of Roche's Avastin drug with new chemotherapy treatments in patients whose cancer did not improve with its first use. More
Novartis Chairman Steps Down, Shares Jump
Daniel Vasella announced that he is stepping down as chairman of Novartis and will be replaced by Bayer executive Joerg Reinhardt. More
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them. More
